Immunotherapy plus chemo for children with hard-to-treat rhabdomyosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests if adding the immunotherapy drug Pucotenlimab to standard chemotherapy is safe and effective for children and teens with a type of muscle cancer (rhabdomyosarcoma) that is hard to treat. It may offer a new option for patients whose tumors are difficult to remove with surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 18 years old.
- Have a new diagnosis of intermediate to high-risk rhabdomyosarcoma that is hard to remove with surgery.
- Have at least one tumor that can be measured on scans.
- Not have received any prior PD-1 or PD-L1 immunotherapy.
- Not have already had chemotherapy, radiation, or surgery (except a biopsy) for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy (pucotenlimab), a targeted therapy (lenvatinib), and chemotherapy for children with advanced or relapsed hepatoblastoma that hasn't responded to prior treatment. The goal is to see if this combination can help shrink or control the tumor.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
This trial tests whether adding all-trans retinoic acid to a standard chemotherapy regimen (VAC) can improve outcomes for people with intermediate-to-high-risk rhabdomyosarcoma. It is for those who have not had prior cancer drug treatment and have adequate organ function.
This trial tests a new immunotherapy drug, pucotenlimab, for children and teens with a rare cancer called lymphoepithelioma-like carcinoma (LECC). The goal is to see if the drug is safe and helps shrink tumors.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.